metastatic/advanced hepatocellular cancer (mHCC) | |
mHCC - 1st line (L1) | |
atezolizumab plus cabozantinib | COSMIC-312 |
Study type:
delta: difference in rate or median (if available)
- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy -